TrialBlood advances2023

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.

Nitin Jain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.